QPS offers automated DNA and RNA isolation from various matrices of clinical samples, including whole blood, plasma, serum, tissues, biopsy sections, or cultural cells. We guaranteed to deliver top quality starting material to ensure successful downstream molecular applications such as genotyping, RT-PCR, and Genechip® microarray expression analysis. Since DNA samples are valuable genetic material for future retrospective study when adverse effect issues are emerged, DNA banking has become a common but necessary practice in majority of the clinical study protocols.

Genotyping testing will provide genetic basis for toxicity prediction, dosing determination, and treatment decision makings. Examples are UGT1A1 genotyping for Irinotecan toxicity prediction, CYP2C9 genotyping for warfarin dosing optimization, and CYP2D6 genotyping to help tamoxifen therapy management for breast cancer patients.

Genetic biomarkers, such as ApoE genotyping, are used to support patient inclusion/exclusion decision makings amd patient selection of ApoE4 carriers and ApoE4 non-carriers in Alzheimer's disease clinical studies. To support patient inclusion/exclusion decision making, we offer 48-72 hours turnaround.

Changes in CpG methylation level in the target genes may serve as a new biomarker for early diagnosis of cancer and for therapy monitoring. For example, CpG methylation levels of the tumor suppressor gene p16 may be associated with multiform glioblastoma brain cancer progression. This can be determined efficiently by pyrosequencing technology.

QPS supports RNA expression analysis of clinical samples by qRT-PCR for drug efficacy and safety evaluation. We also perform western blot analysis, functional assays, and cell-based assays.

Genomic Biomarkers:

For preclinical drug development, genomic biomarkers, such as CpG methylation patterns or RNA expression profiling, will provide new surrogate biomarkers for drug efficacy and drug safety evaluation.